Mapping Rehabilitation Needs Across the U.S.‐Mexico Border: A Cross‐Sectional Geographic Analysis
PM&R · 2026-11 · 18 (S3)
DOI: 10.1002/pmrj.29_70259 ↗Kurz gefasst
Fachartikel in der Zeitschrift PM&R, online erschienen am 10.11.2026. Verfasst von Kelly Dong und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Background and/or Objectives: Patients admitted to inpatient rehabilitation facilities (IRFs), including those with spinal cord injury, stroke, traumatic brain injury, and major orthopedic conditions, remain at elevated risk of venous thromboembolism (VTE).Pharmacologic prophylaxis with enoxaparin is essential to safe rehabilitation care and requires coordinated oversight among physiatrists, nursing, pharmacy, and quality teams.Following a prior manufacturer change prompted by device concerns, acquisition costs increased substantially.An interdisciplinary reassessment evaluated whether a manufacturer transition could reduce cost while maintaining prophylaxis delivery and patient safety.
Design
Pharmacist-led medication use evaluation comparing pre-and post-transition periods.
Setting
Academic inpatient rehabilitation facility.
Participants
Adult inpatients receiving enoxaparin for VTE prophylaxis.
Interventions
An interdisciplinary pharmacy-led review evaluated transition to a lower-cost enoxaparin manufacturer.The pre-transition period included April 2024-August 2025 and the post-transition period included October 2025-January 2026; September 2025 was excluded as a transition month.Acquisition cost was measured using weighted average cost per syringe.Prophylaxis delivery was assessed using medication administration record data normalized to patient-days (administrations per 1,000 patient-days).Safety surveillance included review of internal event reports for device-related concerns.Main Outcome Measures: Change in acquisition cost per syringe, VTE prophylaxis delivery rate, and devicerelated safety events.
Results
The weighted acquisition cost was decreased by 62%.Prophylaxis delivery remained stable (525.5 vs 573.5 administrations per 1,000 patient-days; rate ratio 1.09).No increase in reported VTE events or safety concerns was identified.
Conclusions
Manufacturer transition achieved substantial cost reduction while maintaining prophylaxis delivery and demonstrating no adverse safety signal in a high-risk rehabilitation population.
Zitieren
APA
Dong, K., Velasquez, L., Tamayo, N., & Cobos, H. (2026). Mapping Rehabilitation Needs Across the U.S.‐Mexico Border: A Cross‐Sectional Geographic Analysis. PM&R, 18(S3). https://doi.org/10.1002/pmrj.29_70259
Vancouver
Dong K, Velasquez L, Tamayo N, Cobos H. Mapping Rehabilitation Needs Across the U.S.‐Mexico Border: A Cross‐Sectional Geographic Analysis. PM&R. 2026;18(S3). doi:10.1002/pmrj.29_70259
BibTeX
@article{Dong2026,
author = {Dong, Kelly and Velasquez, Lauren and Tamayo, Nina and Cobos, Helena},
title = {Mapping Rehabilitation Needs Across the U.S.‐Mexico Border: A Cross‐Sectional Geographic Analysis},
journal = {PM&R},
year = {2026},
volume = {18},
number = {S3},
doi = {10.1002/pmrj.29_70259}
}
EUVIMED